AVA Pharmaceuticals (Pvt) Ltd company negotiates for the certificate to release Edurant, Juluca and Odefsey generic drugs

AVA Pharmaceuticals (Pvt) Ltd company reports the start of negotiations for acquiring the patent right to produce Edurant, Juluca and Odefsey generic preparations, which analogs are lacking on the market for today. It is referred to Avaril, Stoffi and Eveta drug products correspondingly.

AVA Pharmaceuticals (Pvt) Ltd company reports the start of negotiations for acquiring the patent right to produce Edurant, Juluca and Odefsey generic preparations, which analogs are lacking on the market for today. It is referred to Avaril, Stoffi and Eveta drug products correspondingly.

Antiretroviral agents are used to treat HIV positive patients. Since a one-month course of HIV treatment with original preparations costs 1500 dollars, only 20-30% of the population of rich countries can afford it. The release of generic drugs is a distinct possibility to live life to the fullest for average virus carriers. Approximately 12 000 rubles is the cost of a treatment course with generic medicines.

Reducing the viral load to a zero threshold is possible with a correctly developed treatment regime and daily taking a dose of generic drugs within 6 consecutive months will reduce the viral load to a zero threshold. Given constant taking these preparations can maintain permanent zero viremia for the term of one’s life.

The generic drugs composition includes the same active substances as those of original preparations: Avaril (Rilpivirine), Stoffi (Dolutegravir+Rilpivirine) and Eveta (TAF+emtricitabine+rilpivirine). The therapeutic effect will remain as high as in the case of original drugs. A treatment schedule with the generics is simple. One needs to take the drugs regularly – one pill daily at one and the same time each day.

FDA approval is not required for generic drugs manufacturing since the active pharmaceutical components used have been clinically tested.